Nirmatrelvir Plus Ritonavir for Ambulatory COVID-19: Expanding Evidence, Expanding Role

Ann Intern Med. 2023 Jan;176(1):133-134. doi: 10.7326/M22-3427. Epub 2022 Dec 13.

Authors

George L Anesi¹, Christina Maguire²

Affiliations

¹ Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
² Department of Pharmacy, Penn Presbyterian Medical Center, Philadelphia, Pennsylvania.

PMID: 36508735
DOI: 10.7326/M22-3427

No abstract available

Publication types

Comment

MeSH terms

COVID-19 Drug Treatment
COVID-19*
Humans
Lactams
Nitriles
Ritonavir* / therapeutic use

Substances

Ritonavir
Lactams
Nitriles

Grants and funding

K23 HL161353/HL/NHLBI NIH HHS/United States